RU2010141996A - Ингибитор ммр-2 и/или ммр-9 - Google Patents
Ингибитор ммр-2 и/или ммр-9 Download PDFInfo
- Publication number
- RU2010141996A RU2010141996A RU2010141996/04A RU2010141996A RU2010141996A RU 2010141996 A RU2010141996 A RU 2010141996A RU 2010141996/04 A RU2010141996/04 A RU 2010141996/04A RU 2010141996 A RU2010141996 A RU 2010141996A RU 2010141996 A RU2010141996 A RU 2010141996A
- Authority
- RU
- Russia
- Prior art keywords
- mmp
- inhibitor
- group
- substituents
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
1. Ингибитор ММР-2 и/или ММР-9, включающий в качестве активного ингредиента, по меньшей мере, одно соединение, выбранное из группы, состоящей из производных тиазола, представленных формулой 1): ! ! где R1 представляет собой фенильную группу, которая может иметь от 1 до 3 низших алкоксигрупп в качестве заместителей у фенильного кольца, и R2 представляет собой пиридильную группу, которая может иметь от 1 до 3 карбоксильных групп в качестве заместителей у пиридинового кольца, и их солей. ! 2. Ингибитор ММР-2 и/или ММР-9 по п.1, где производное тиазола представляет собой 6-[2-(3,4-диэтоксифенил)тиазол-4-ил]пиридин-2-карбоновую кислоту или ее соль. ! 3. Ингибитор ММР-2 и/или ММР-9 по п.1 или 2 для применения при лечении фиброза. ! 4. Ингибитор ММР-2 и/или ММР-9 по п.1 или 2 для применения при лечении легочной эмфиземы.
Claims (4)
1. Ингибитор ММР-2 и/или ММР-9, включающий в качестве активного ингредиента, по меньшей мере, одно соединение, выбранное из группы, состоящей из производных тиазола, представленных формулой 1):
где R1 представляет собой фенильную группу, которая может иметь от 1 до 3 низших алкоксигрупп в качестве заместителей у фенильного кольца, и R2 представляет собой пиридильную группу, которая может иметь от 1 до 3 карбоксильных групп в качестве заместителей у пиридинового кольца, и их солей.
2. Ингибитор ММР-2 и/или ММР-9 по п.1, где производное тиазола представляет собой 6-[2-(3,4-диэтоксифенил)тиазол-4-ил]пиридин-2-карбоновую кислоту или ее соль.
3. Ингибитор ММР-2 и/или ММР-9 по п.1 или 2 для применения при лечении фиброза.
4. Ингибитор ММР-2 и/или ММР-9 по п.1 или 2 для применения при лечении легочной эмфиземы.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008065455 | 2008-03-14 | ||
JP2008-065455 | 2008-03-14 | ||
PCT/JP2009/055545 WO2009113736A1 (en) | 2008-03-14 | 2009-03-13 | Mmp-2 and/or mmp-9 inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2010141996A true RU2010141996A (ru) | 2012-04-20 |
RU2487131C2 RU2487131C2 (ru) | 2013-07-10 |
Family
ID=40613081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010141996/04A RU2487131C2 (ru) | 2008-03-14 | 2009-03-13 | Ингибитор ммр-2 и/или ммр-9 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20110054179A1 (ru) |
EP (1) | EP2280708A1 (ru) |
JP (2) | JP2011513203A (ru) |
KR (1) | KR20100135255A (ru) |
CN (3) | CN103622962A (ru) |
AR (1) | AR070882A1 (ru) |
AU (1) | AU2009224209B2 (ru) |
BR (1) | BRPI0909288A2 (ru) |
CA (1) | CA2718005A1 (ru) |
IL (2) | IL207816A0 (ru) |
MX (1) | MX2010010073A (ru) |
NZ (1) | NZ587591A (ru) |
RU (1) | RU2487131C2 (ru) |
SG (1) | SG188852A1 (ru) |
TW (1) | TWI436767B (ru) |
UA (1) | UA108979C2 (ru) |
WO (1) | WO2009113736A1 (ru) |
ZA (1) | ZA201005991B (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130184272A1 (en) * | 2010-09-17 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Diabetes therapeutic agent |
JP7328323B2 (ja) | 2018-08-17 | 2023-08-16 | ノバルティス アーゲー | SMARCA2/BRM ATPase阻害剤としての尿素化合物及び組成物 |
WO2023192880A2 (en) * | 2022-03-29 | 2023-10-05 | The Trustees Of The University Of Pennsylvania | Methods of treating, ameliorating and/or preventing fibrodysplasia ossificans progressiva and heterotopic ossification, and kits for the same |
WO2023204170A1 (ja) * | 2022-04-18 | 2023-10-26 | 大正製薬株式会社 | Mmp2阻害作用を有する化合物を有効成分として含有する肺の炎症及び線維症の予防又は治療薬 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA962269A (en) * | 1971-05-05 | 1975-02-04 | Robert E. Grahame (Jr.) | Thiazoles, and their use as insecticides |
US5639770A (en) * | 1992-05-29 | 1997-06-17 | Otsuka Pharmaceutical Co., Ltd. | Thiazole derivatives |
JP3622015B2 (ja) * | 1992-10-08 | 2005-02-23 | 敏一 中村 | 肺傷害治療剤 |
MY128323A (en) * | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
AU2001238288A1 (en) * | 2000-02-16 | 2001-08-27 | University Of Nebraska Medical Center | Method and compositions for treating fibrotic diseases |
GB0007405D0 (en) * | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
EP1199074A1 (en) * | 2000-09-15 | 2002-04-24 | Warner-Lambert Company | Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
WO2002046186A1 (fr) * | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Dérivés thiazole substitués porteurs de groupes 3-pyridyl, procédé d'élaboration et leur utilisation |
JP3713577B2 (ja) * | 2001-07-24 | 2005-11-09 | 大塚製薬株式会社 | 慢性閉塞性肺疾患治療薬 |
CN1267097C (zh) * | 2001-07-24 | 2006-08-02 | 大塚制药株式会社 | 噻唑类衍生物在制备可用于治疗慢性阻塞性肺病的药物中的用途 |
CA2473706A1 (en) * | 2002-02-05 | 2003-08-14 | Dainippon Pharmaceutical Co., Ltd. | Heterocyclic compounds having elastase-inhibitory activity and intermediates thereof |
GB0217504D0 (en) * | 2002-07-29 | 2002-09-04 | Novartis Ag | Organic compounds |
BR0313755A (pt) * | 2002-08-23 | 2005-06-21 | Rigel Pharmaceuticals Inc | Composto, métodos para inibir a replicação ou proliferação de um vìrion da hepatite c e para tratar ou prevenir uma infecção por hcv, e, composição |
UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
WO2006008118A1 (en) * | 2004-07-16 | 2006-01-26 | Proteosys Ag | Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents |
DK1888033T3 (da) * | 2005-06-09 | 2014-05-26 | Meda Ab | Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme |
WO2007123953A2 (en) * | 2006-04-19 | 2007-11-01 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
TWI436761B (zh) * | 2006-06-19 | 2014-05-11 | Otsuka Pharma Co Ltd | 使用噻唑衍生物之方法 |
ME01901B (me) * | 2006-07-05 | 2014-12-20 | Astrazeneca Ab | Kombinacija inhibitora HMG-CoA reduktaze atorvastatina ili simvastatina sa fosfodiesteraza 4 inhibitorom, kao što je roflumilast za lečenje inflamatornih pulmonarnih oboljenja |
-
2009
- 2009-03-13 UA UAA201012145A patent/UA108979C2/ru unknown
- 2009-03-13 BR BRPI0909288-9A patent/BRPI0909288A2/pt not_active IP Right Cessation
- 2009-03-13 CN CN201310533925.8A patent/CN103622962A/zh active Pending
- 2009-03-13 NZ NZ587591A patent/NZ587591A/xx not_active IP Right Cessation
- 2009-03-13 US US12/922,374 patent/US20110054179A1/en not_active Abandoned
- 2009-03-13 TW TW098108215A patent/TWI436767B/zh not_active IP Right Cessation
- 2009-03-13 CN CN2009801087584A patent/CN101969949B/zh not_active Expired - Fee Related
- 2009-03-13 WO PCT/JP2009/055545 patent/WO2009113736A1/en active Application Filing
- 2009-03-13 AR ARP090100897A patent/AR070882A1/es unknown
- 2009-03-13 MX MX2010010073A patent/MX2010010073A/es active IP Right Grant
- 2009-03-13 JP JP2010536255A patent/JP2011513203A/ja active Pending
- 2009-03-13 CN CN2013103353496A patent/CN103463084A/zh active Pending
- 2009-03-13 AU AU2009224209A patent/AU2009224209B2/en not_active Ceased
- 2009-03-13 EP EP09719488A patent/EP2280708A1/en not_active Withdrawn
- 2009-03-13 CA CA2718005A patent/CA2718005A1/en not_active Abandoned
- 2009-03-13 RU RU2010141996/04A patent/RU2487131C2/ru not_active IP Right Cessation
- 2009-03-13 KR KR1020107022827A patent/KR20100135255A/ko not_active Application Discontinuation
- 2009-03-13 SG SG2013016746A patent/SG188852A1/en unknown
-
2010
- 2010-08-23 ZA ZA2010/05991A patent/ZA201005991B/en unknown
- 2010-08-26 IL IL207816A patent/IL207816A0/en unknown
-
2013
- 2013-09-17 IL IL228484A patent/IL228484A0/en unknown
-
2014
- 2014-09-01 JP JP2014176705A patent/JP2014221839A/ja not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
UA108979C2 (ru) | 2015-07-10 |
CA2718005A1 (en) | 2009-09-17 |
CN103622962A (zh) | 2014-03-12 |
CN101969949B (zh) | 2013-12-25 |
ZA201005991B (en) | 2011-10-26 |
AU2009224209A1 (en) | 2009-09-17 |
EP2280708A1 (en) | 2011-02-09 |
BRPI0909288A2 (pt) | 2015-08-18 |
CN103463084A (zh) | 2013-12-25 |
TW200942237A (en) | 2009-10-16 |
KR20100135255A (ko) | 2010-12-24 |
IL207816A0 (en) | 2010-12-30 |
JP2014221839A (ja) | 2014-11-27 |
RU2487131C2 (ru) | 2013-07-10 |
NZ587591A (en) | 2012-10-26 |
CN101969949A (zh) | 2011-02-09 |
MX2010010073A (es) | 2010-10-04 |
TWI436767B (zh) | 2014-05-11 |
JP2011513203A (ja) | 2011-04-28 |
AR070882A1 (es) | 2010-05-12 |
US20110054179A1 (en) | 2011-03-03 |
WO2009113736A1 (en) | 2009-09-17 |
SG188852A1 (en) | 2013-04-30 |
AU2009224209B2 (en) | 2015-01-22 |
IL228484A0 (en) | 2013-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009136178A (ru) | Нематоцидная композиция и способ ее применения | |
RU2014114466A (ru) | ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА | |
MEP10009A (en) | 1-heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-hpyrrole derivatives as acid secretion inhibitors | |
AR059622A1 (es) | Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles | |
RU2006101890A (ru) | Производные тиазолилпиперидина в качестве ингибиторов мпб | |
NO20092770L (no) | Nye aminopyrimidinderivater som PLK1-inhibitorer | |
CY1110800T1 (el) | Μεθανοσουλφονικα αλατα αβιρατερονης-3-εστερων και ανακτηση αλατων αβιρατερονης-3-εστερων απο διαλυμα σε μεθυλο τριτ-βουτυλαιθερα | |
RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
ATE442356T1 (de) | 1-essigsäureindolderivate mit pgd2- antagonistischer wirkung | |
RS51471B (en) | BIPHYNYLOXYXIC ACID DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | |
RU2007139453A (ru) | Гетеробициклические ингибиторы вируса гепатита с (hcv) | |
NO20065719L (no) | I det vesentlige rene 2-{[2-(2-metylamino-pyrimidin-4-yl)-1H-indol-5-karbonyl]-amlno}-3-(fenylpyridin-2-yl-amino)-propionsyre som en IkB kinaseinhibitor. | |
RS52191B (en) | TETRAHYDROCYCLOPENT (B) INDOLE UNITS AS MODULATORS OF ANDROGENIC RECEPTORS | |
WO2008015280A3 (de) | Wässrige wirkstoffkonzentrate mit herbizider wirkung | |
PE20120171A1 (es) | Sales de adicion de aminas que contienen grupos hidroxilo y/o carboxilicos con derivados de acidos aminonicotinico como inhibidores de dhodh | |
CL2022001844A1 (es) | Compuesto de iminoarilo sustituido con derivado de ácido carboxílico, método de preparación, composición y uso | |
ATE388147T1 (de) | Thiazolderivate als a2b-antagonisten | |
RU2010141996A (ru) | Ингибитор ммр-2 и/или ммр-9 | |
NO20080325L (no) | Forbindelser og deres salter som er spesifikke overfor PPAR-reseptorer og EGF-reseptorer samt deres anvendelse innen medisin | |
DE60306539D1 (de) | Nicht-nukleosidische inhibitoren der reverse transkriptase | |
RU2016120610A (ru) | Производное сульфонамида и его применение в медицине | |
RU2009102270A (ru) | Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы | |
RU2010146954A (ru) | 2-(замещенный фенил)-6-гидрокси или алкокси-5-замещенные-4-пиримидинкарбоксилаты и их применение в качестве гербицидов | |
EA200600878A1 (ru) | Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора ( ppar ) | |
RU2017117179A (ru) | Производные пиридооксазинона в качестве ингибиторов tnap |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160314 |